Talphera Inc

CEO Angotti boosts Talphera stake to 800k shares, signaling bullish outlook as nafamostat data nears—investors eye potential upside.

CEO insider buy of Tal­phera shares sparks short‑term optimism amid regulatory uncertainty and a hopeful pipeline for Niyad.

Tal Phera’s insider buying and new warrants hint at rising investor confidence as its peripheral opioid pipeline shows promising pain‑relief data and a clear path toward FDA approval and potential shareholder gains.